Cell Reports-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2020-07-15 这是一个昵称

好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的

224 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2019-05-21 omegaphd

2019年5月9号投稿，5月21号让转投iScience……

255 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2021-10-26 826449277

偏重的研究方向：医学;综合;生物学
经验分享：请问和sicnece signaling比哪个难度大

229 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2023-03-09 ms5000001366657176 来自江苏省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错

1 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2022-06-02 SCI 99

请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？

161 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2021-01-12 疯狂的丫头0731

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。

229 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2021-09-10 张晓梅-Xiaomei Zhang

看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了

231 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2021-01-27 1026240635

之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。

142 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2020-06-29 mswert122

8.109分，还是很牛的，没有成为水刊

189 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=802820, encodeId=47b980282092, content=好杂志，工作比较solid，虽然比不了pnas（直投）和embo，但是也算很好的了，比很多同分数的杂志比如JHO之类强太多了，影响力也不是一个档次的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/14/2d0413f4fd3b4a5f1acc9ccc7d585f61.jpg, createdBy=b9cb2546102, createdName=这是一个昵称, createdTime=Wed Jul 15 04:02:22 CST 2020, time=2020-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=571266, encodeId=65d75e126657, content=2019年5月9号投稿，5月21号让转投iScience……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=255, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/01/05fe1b096c68a56351e8999feca73478.jpg, createdBy=c0fa1663065, createdName=omegaphd, createdTime=Tue May 21 00:00:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063947, encodeId=90b2106394e9f, content=偏重的研究方向：医学;综合;生物学 经验分享：请问和sicnece signaling比哪个难度大, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bcd2757433, createdName=826449277, createdTime=Tue Oct 26 06:34:58 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2118532, encodeId=4857211853246, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：好杂志，推荐，刚刚中了，作为一个研究生，是不是还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de436514664, createdName=ms5000001366657176, createdTime=Thu Mar 09 19:15:29 CST 2023, time=2023-03-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1223966, encodeId=142e12239666a, content=请教各位前辈，现在这个杂志发表前要求提供PCR原始数据嘛？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e5e4748995, createdName=SCI 99, createdTime=Thu Jun 02 01:00:07 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=916044, encodeId=e55b916044c5, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿10天 with editor，几天后送审，一审时间5周左右，圣诞节后就给了意见，效率很高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=229, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Tue Jan 12 21:28:37 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016312, encodeId=7a5d101631224, content=看趋势Cell集团是想把cell reports推到10多分的档次，用来接收20分掉下来的文章。比以前难投了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211026/130f1b4c56624fe29a27048308d1902f/4f51757ef2084492b45315805618ca56.jpg, createdBy=832b2252477, createdName=张晓梅-Xiaomei Zhang, createdTime=Fri Sep 10 13:03:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920274, encodeId=cf4c9202e441, content=之前投Cancer Cell送审后被拒，编辑说Cell Reports主编对我们文章很感兴趣，但我们没有转投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=142, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=05323119086, createdName=1026240635, createdTime=Wed Jan 27 13:19:46 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800422, encodeId=8e24800422b5, content=8.109分，还是很牛的，没有成为水刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=189, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, createdBy=2a791737770, createdName=mswert122, createdTime=Mon Jun 29 21:41:00 CST 2020, time=2020-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2182232, encodeId=9a4a21822324e, content=请问今年影响因子能涨吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c715296884, createdName=ms9000001460504456, createdTime=Wed Jan 17 17:00:10 CST 2024, time=2024-01-17, status=1, ipAttribution=广东省)]

2024-01-17 ms9000001460504456 来自广东省

请问今年影响因子能涨吗？

22 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务